🎉 M&A multiples are live!
Check it out!

Chimerix Valuation Multiples

Discover revenue and EBITDA valuation multiples for Chimerix and similar public comparables like Julphar, Benevolent AI, and Vivoryon Therapeutics.

Chimerix Overview

About Chimerix

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.


Founded

2000

HQ

United States of America
Employees

81

Website

chimerix.com

Financials

LTM Revenue $1.7M

LTM EBITDA n/a

EV

$670M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Chimerix Financials

Chimerix has a last 12-month revenue of $1.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Chimerix achieved revenue of $0.2M and an EBITDA of -$96.5M.

Chimerix expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Chimerix valuation multiples based on analyst estimates

Chimerix P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.3M $0.2M XXX XXX XXX
Gross Profit $33.4M $0.3M XXX XXX XXX
Gross Margin 10302% 153% XXX XXX XXX
EBITDA -$93.0M -$96.5M XXX XXX XXX
EBITDA Margin -28696% -45506% XXX XXX XXX
Net Profit $172M -$82.1M XXX XXX XXX
Net Margin 53138% -38724% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Chimerix Stock Performance

As of April 15, 2025, Chimerix's stock price is $9.

Chimerix has current market cap of $801M, and EV of $670M.

See Chimerix trading valuation data

Chimerix Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$670M $801M XXX XXX XXX XXX $-0.97

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Chimerix Valuation Multiples

As of April 15, 2025, Chimerix has market cap of $801M and EV of $670M.

Chimerix's trades at 382.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Chimerix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Chimerix and 10K+ public comps

Chimerix Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $670M XXX XXX XXX
EV/Revenue 3159.9x XXX XXX XXX
EV/EBITDA -6.9x XXX XXX XXX
P/E -9.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -8.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chimerix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Chimerix Valuation Multiples

Chimerix's NTM/LTM revenue growth is 1201%

Chimerix's revenue per employee for the last fiscal year averaged $3K, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Chimerix's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Chimerix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Chimerix and other 10K+ public comps

Chimerix Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -35% XXX XXX XXX XXX
EBITDA Margin -45506% XXX XXX XXX XXX
EBITDA Growth 4% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -44306% XXX XXX XXX XXX
Revenue per Employee $3K XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 10474% XXX XXX XXX XXX
R&D Expenses to Revenue 35176% XXX XXX XXX XXX
Opex to Revenue 45650% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Chimerix Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Chimerix M&A and Investment Activity

Chimerix acquired  XXX companies to date.

Last acquisition by Chimerix was  XXXXXXXX, XXXXX XXXXX XXXXXX . Chimerix acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Chimerix

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Chimerix

When was Chimerix founded? Chimerix was founded in 2000.
Where is Chimerix headquartered? Chimerix is headquartered in United States of America.
How many employees does Chimerix have? As of today, Chimerix has 81 employees.
Who is the CEO of Chimerix? Chimerix's CEO is Mr. Michael T. Andriole.
Is Chimerix publicy listed? Yes, Chimerix is a public company listed on NAS.
What is the stock symbol of Chimerix? Chimerix trades under CMRX ticker.
When did Chimerix go public? Chimerix went public in 2013.
Who are competitors of Chimerix? Similar companies to Chimerix include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Chimerix? Chimerix's current market cap is $801M
What is the current revenue of Chimerix? Chimerix's last 12-month revenue is $1.7M.
What is the current EV/Revenue multiple of Chimerix? Current revenue multiple of Chimerix is 382.8x.
What is the current revenue growth of Chimerix? Chimerix revenue growth between 2023 and 2024 was -35%.
Is Chimerix profitable? Yes, Chimerix is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.